Medivation downgraded to Hold from Buy at Needham Needham downgraded Medivation citing valuation as it believes near-term market dominance in the pre-chemo prostate cancer space is being priced into shares at current levels.
News For MDVN From The Last 14 Days
Check below for free stories on MDVN the last two weeks.
Medivation upgraded to Buy at Canaccord As reported previously, Canaccord upgraded Medivation to Buy from Hold citing the pre-chemotherapy opportunity and meaningful incremental share gains of its Xtandi drug. Canaccord raised its price target on Medivation to $132 from $60.